When to Stop

• Cardiomyopathy / heart failure with chronic use — multiple 2023-2024 case reports. Mechanism: sustained catecholamine-driven LV hypertrophy → fibrosis → dilated cardiomyopathy. Risk dose- and duration-dependent. Particular concern for combat athletes who already place chronic cardiovascular load on the heart.
• Sudden cardiac death — extremely rare; FDA black-box notes risk in patients with structural cardiac abnormalities. ECG screening recommended before initiation.
• Stroke / MI — rare, dose-related, more common with abuse / very high doses
• Psychosis (amphetamine-induced) — typically with higher doses or in genetically susceptible individuals (family history of psychosis is a red flag). Can persist after discontinuation in rare cases.
• Mania / hypomania switch — particularly in undiagnosed bipolar patients
• Serotonin syndrome — rare but possible if combined with MAOIs, certain antidepressants, MDMA
• Stevens-Johnson Syndrome — rare class effect, less established than with modafinil
• Vasculopathy / Raynaud's-like phenomena — peripheral vasoconstriction, occasionally reported with chronic use
• Stimulant use disorder (DSM-5) — actual addiction. Higher risk in non-ADHD users.
• Withdrawal syndrome on discontinuation — fatigue, hypersomnia, depression, increased appetite, anhedonia. Usually 3-7 days for acute phase, can extend 2-4 weeks for protracted symptoms.
• First 2 weeks: Cardiovascular adjustment (BP, HR), anxiety, sleep impact. If BP rises >10 mmHg systolic sustained or HR >100 resting, reconsider.
• Months 1-6: Tolerance development, dose creep risk, dependence patterns. The "is this still working as well?" question with a yes-up-the-dose answer is the start of trouble.
• Year 1+: Cardiovascular structural changes (echocardiogram if any chest discomfort, palpitations, or exercise intolerance). Mood baseline drift (depression on off days = pseudo-baseline shift).